Abstract
Synaptic dysfunction is involved in early stages of Alzheimers disease (AD). Amyloid-β peptides (Aβ), a neuropathologic hallmark of the disease, have been shown to alter synaptic function. Given that Aβ is present in different forms including monomeric, oligomeric and fibrillar species, we have investigated whether fibrillar Aβ impairs synaptic function. Here we report that a synthetic fibrillar form of Aβ impairs the late protein-synthesis dependent phase of LTP without affecting the early protein-synthesis independent phase. These findings add to previous reports that Aβ oligomers are highly toxic to cells and might cause synaptic dysfunction, and suggest that a therapeutic intervention in AD should include the use of drugs inhibiting and disassembling fibril formation in addition to drugs inhibiting oligomers formation.
Keywords: Synapse, amyloid, Alzheimer's disease, synaptic plasticity, fibrils
Current Alzheimer Research
Title: Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Volume: 3 Issue: 3
Author(s): Daniela Puzzo and Ottavio Arancio
Affiliation:
Keywords: Synapse, amyloid, Alzheimer's disease, synaptic plasticity, fibrils
Abstract: Synaptic dysfunction is involved in early stages of Alzheimers disease (AD). Amyloid-β peptides (Aβ), a neuropathologic hallmark of the disease, have been shown to alter synaptic function. Given that Aβ is present in different forms including monomeric, oligomeric and fibrillar species, we have investigated whether fibrillar Aβ impairs synaptic function. Here we report that a synthetic fibrillar form of Aβ impairs the late protein-synthesis dependent phase of LTP without affecting the early protein-synthesis independent phase. These findings add to previous reports that Aβ oligomers are highly toxic to cells and might cause synaptic dysfunction, and suggest that a therapeutic intervention in AD should include the use of drugs inhibiting and disassembling fibril formation in addition to drugs inhibiting oligomers formation.
Export Options
About this article
Cite this article as:
Puzzo Daniela and Arancio Ottavio, Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632871
DOI https://dx.doi.org/10.2174/156720506777632871 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Xanthine Oxidase by Natural Products as a Therapeutic Approach for Mental Disorders
Current Pharmaceutical Design Identification of Bioactive Natural Products by Pharmacophore-Based Virtual Screening
Current Pharmaceutical Design Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Letters in Drug Design & Discovery Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Potential Role of Neuroimaging Markers for Early Diagnosis of Dementia in Primary Care
Current Alzheimer Research Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Current Pharmaceutical Design The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry 18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features
Current Alzheimer Research